Li Hui, Liu Fu-Yuan, Li Xiao-Lan, Li Xiao-Mei, Zhu Lei
Department of Cardiovascularology, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei 441001, P.R. China.
Exp Ther Med. 2016 Aug;12(2):979-982. doi: 10.3892/etm.2016.3363. Epub 2016 May 19.
The aim of the study was to compare the clinical effects of carvedilol and trimetazidine for the treatment of alcoholic cardiomyopathy. A total of 60 patients diagnosed with alcoholic cardiomyopathy were enrolled in the study. The patients were randomly divided into the carvedilol (n=20), trimetazidine (n=20) and control (n=20) groups. The patients in the control, carvedilol and trimetazidine groups were treated with conventional drugs, conventional drugs + carvedil and conventional drugs + trimetazidine respectively, for 12 weeks. The patients were compared for their heart functions [left ventricular ejection fraction (LVEF), C-reactive protein (CRP) and 6 min walking], heart rate, blood pressure and heart enlargement (cardiothoracic proportion and left ventricular diameter) before and after treatment. The parameters studied for heart functions, heart rate, blood pressure, heart enlargement, clinical effects before and after treatment were statistically insignificant (p>0.05). After treatment, the carvedilol and trimetazidine groups showed higher LVEF and CRP, longer walking distance in 6 min, as well as lower heart rate and blood pressure (both systolic and diastolic) compared to the control group. Similarly, the cardiothoracic proportion and left ventricular internal diameter for the carvedilol and trimetazidine groups was lower than those of the control group, with better clinical effects (p<0.05). In conclusion, the curative effects of the carvedilol and trimetazidine groups of alcoholic myocardiopathy similar. Both are safe agents that may improve the cardiac function and heart expansion of patients.
本研究的目的是比较卡维地洛和曲美他嗪治疗酒精性心肌病的临床效果。共有60例被诊断为酒精性心肌病的患者纳入本研究。患者被随机分为卡维地洛组（n = 20）、曲美他嗪组（n = 20）和对照组（n = 20）。对照组、卡维地洛组和曲美他嗪组患者分别接受常规药物、常规药物+卡维地洛和常规药物+曲美他嗪治疗12周。比较患者治疗前后的心功能[左心室射血分数（LVEF）、C反应蛋白（CRP）和6分钟步行距离]、心率、血压及心脏扩大情况（心胸比例和左心室直径）。所研究的治疗前后的心功能、心率、血压、心脏扩大及临床效果等参数差异无统计学意义（p>0.05）。治疗后，与对照组相比，卡维地洛组和曲美他嗪组显示出更高的LVEF和CRP、更长的6分钟步行距离，以及更低的心率和血压（收缩压和舒张压）。同样，卡维地洛组和曲美他嗪组的心胸比例和左心室内径低于对照组，临床效果更好（p<0.05）。总之，卡维地洛组和曲美他嗪组治疗酒精性心肌病的疗效相似。两者都是安全的药物，均可改善患者的心功能和心脏扩大情况。
